Aislinn Antrim, MA, Assistant Managing Editor

Vusolimogene oderparepvec is in development for the treatment of multiple skin cancers either alone or in combination with anti-PD1 therapy.

The FDA previously granted Fast Track Designation for the combination of lifileucel and pembrolizumab in metastatic melanoma.

Based on event-free survival and pathologic complete response results, the FDA approved nivolumab in combination with platinum-doublet chemotherapy in March 2022.

Numbers have remained below prepandemic levels.

Those hospitalized for COVID-19 were 21% more likely to develop shingles.

If all HHC agencies adopted policies requiring staff influenza vaccinations, the researchers predicted an 11.25% reduction in the rate of hospital transfers due to respiratory infections.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being evaluated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Common issues that affect patient outcomes include economic stability, education access, health care access, social and community context, and neighborhood environment.

Session explores data from both the SCORED trial of sotagliflozin and the REVERSE-IT trial investigating bentracimab to reverse the antiplatelet effects of ticagrelor.

An 11-fold increase in geometric mean neutralizing antibody titers was reported at 2 weeks after the second booster compared to 5 months after the first booster dose.

Patients in the atogepant 60 mg daily and 30 mg twice daily treatment arms of the study experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively.

Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

The death rate from cervical cancer has dropped by more than 50% since 1975.

Use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer resulted in meaningful anti-tumor activity, consistent safety, and favorable tolerability.

Hormone replacement therapy can improve quality of life without necessarily increasing the risk of recurrence.

Speakers at the annual Society of Gynecologic Oncology annual meeting emphasized the theme of building bridges and breaking barriers to advance gynecologic care.

Despite early excitement about the potential for pharmacists to prescribe COVID-19 oral antivirals, the program does not provide that ability.

Researchers found that in a program of biennial screening of women aged 50 to 74 years, approximately 1 in 7 screen-detected breast cancer cases would be overdiagnosed.

The proof-of-concept study is expected to announce topline safety, tolerability, and immunogenicity results by the end of 2022.

Durvalumab plus chemotherapy did not increase the discontinuation rate due to adverse events compared to chemotherapy alone.

Durable responses mark a significant advancement over chemotherapy, which may have only been effective for 9 to 10 months.

Study findings support the role of tezepelumab-ekko as a first-in-class treatment for a broad population of patients living with severe asthma, irrespective of biomarker levels.

Filgrastim-ayow is indicated for the treatment of neutropenia, which is commonly experienced by patients receiving chemotherapy.

A supplemental application was also submitted for an oral suspension formulation to provide an alternative administration option for children.

Any patients aged 60 years or older who does not meet risk-based recommendations can still receive hepatitis B vaccination.

PDS founder and executive chairman Dan Benamoz, RPh, discussed a few of the most exciting speakers and opportunities happening during the conference.

One out of every 4 pharmacists in Georgia said emergency contraception was not available at the store and ended the call.

Data suggest that omicron-specific CD8-positive T cell responses were more than 80% cross-reactive with the CD8-positive T cell response to the original strain of the virus.

Applying these findings in practice could improve clinicians’ ability to offer truly personalized cancer therapy by enabling consideration of toxicity along with other data predicting patients’ responses.

A product containing phosphoric acid as well as alcohol successfully neutralized all of the virus particles.